On October 3, 2024 press releases titled "Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of ...
Quarter Results Abivax presents third quarter 2024 key financial information 14.11.2024 / 22:01 CET/CEST The issuer is solely responsible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback